Denosumab: an investigational drug for the management of postmenopausal osteoporosis

Expert Opinion

(2756) Views  (741) Full article downloads

Author: E Michael Lewiecki

Published Date August 2008 Volume 2008:2(4) Pages 645 - 653

DOI: http://dx.doi.org/10.2147/BTT.S2082

E Michael Lewiecki

New Mexico Clinical Research & Osteoporosis Center, Albuquerque, New Mexico, USA

Abstract: Denosumab (AMG 162) is an investigational fully human monoclonal antibody with a high affinity and specificity for receptor activator of nuclear factor-κB ligand (RANKL), a cytokine member of the tumor necrosis factor family. RANKL, the principal mediator of osteoclastic bone resorption, plays a major role in the pathogenesis of postmenopausal osteoporosis and other skeletal disorders associated with bone loss. Denosumab inhibits the action of RANKL, thereby reducing the differentiation, activity, and survival of osteoclasts, and lowering the rate of bone resorption. Clinical trials have shown that denosumab increases bone mineral density (BMD) and reduces bone turnover in postmenopausal women with low BMD. Studies to evaluate the fracture risk benefit and long-term safety of denosumab in women with postmenopausal osteoporosis (PMO) are ongoing. Denosumab is a potential treatment for PMO and other skeletal disorders.

Keywords: osteoporosis, treatment, denosumab, AMG 162, RANKL, OPG

Other articles by Dr E. Michael Lewiecki